Status:
ACTIVE_NOT_RECRUITING
Risk Factors and Deep Learning Model for CI-AKI
Lead Sponsor:
Xiao Li，MD
Conditions:
AKI - Acute Kidney Injury
Eligibility:
All Genders
18+ years
Brief Summary
Contrast-associated acute kidney injury (CI-AKI) is a sudden and significant decline in renal function resulting from the use of a contrast agent.
Detailed Description
Contrast-associated acute kidney injury (CI-AKI) is a sudden and significant decline in renal function resulting from the use of a contrast agent. Despite the frequent use of iodinated contrast agents...
Eligibility Criteria
Inclusion
- patients who received iodinated contrast agents during hospitalization
- age ≥ 18 years
- hospitalization length ≥ 48 hours
- at least two serum creatinine tests during hospitalization
Exclusion
- patients with stage 4 or 5 chronic kidney disease prior to admission
- patients undergoing hemodialysis, hemofiltration or peritoneal before admission
- a history of nephrectomy or kidney transplantation during hospitalization
- incomplete clinical information
- Serum creatinine always ≤ 40 μmol/L during hospitalization
Key Trial Info
Start Date :
June 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2025
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT06596785
Start Date
June 1 2024
End Date
June 1 2025
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital
Jinan, Shandong, China, 250014